Lomefloxacin is a fluoroquinolone antibiotic that is quite efficacious against many gram negative and gram positive pathogens. Lomefloxacin evince antibacterial effects by modifying DNA gyrase in gram negative pathogens and topoisomerase IV in gram positive pathogens. This study is designed to assess the immunomodulatory effects of lomefloxacin in male albino mice. Three doses of lomefloxacin 12.5 mg/kg, 25 mg/kg and 50 mg/kg were used and delayed type hypersensitivity assay, cyclophosphamide induced neutropenic assay, carbon clearance assay, hemagglutination assay and mice lethality test were performed to evaluate the effects of lomefloxacin on immune system of mice. DTH assay has depicted the significant immunosuppressant potential of lomefloxacin at 25 mg/kg and 50 mg/kg dose. Total leukocyte count have exhibited highly significant reduction (P<0.001) in leukocyte count after cyclophosphamide administration. Differential leukocyte count has shown significant (P<0.01) reduction in lymphocyte count, whereas, highly significant (P<0.001) increase in monocyte count and significant (P<0.05) increase in neutrophil count has been observed. In carbon clearance assay, highly significant (P<0.01) increase in phagocytic index has been noted at 12.5 mg/kg and 25 mg/kg doses. Humoral immune system responses are suppressed in dose dependent manner by both hemagglutination assay (P<0.001) and mice lethality assay (P<0.001). Results clearly depict that lomefloxacin possess quite significant immunomodulatory potential.

Keywords: Cell-mediated. Humoral. Immunomodulatory. Immune response. Lomefloxacin.

INTRODUCTION

Lomefloxacin is a fluoroquinolone antibiotic (Hidaka, Kobayashi et al., 2015). Lomefloxacin exhibits such unique properties that favor treatment of a number of infective diseases and forge them eminently effectual against both gram positive pathogens and gram negative pathogens (Bradley, Jackson, 2011). Lomefloxacin is effective in infections caused by various pathogens including Mycobacterium, Chlamydia and Mycoplasma and is also efficacious in treating community-acquired pneumonia (Walker, 1999). Lomefloxacin evince antibacterial effects by modifying DNA gyrase in gram negative pathogens and topoisomerase IV is the primary target in gram positive organisms (Bearden, Danziger, 2001). It is the fourth most prescribed medicine around the globe (Oliveira, Maniero, Guimaraes, 2015). The prolonged half-life and good tissue penetrating potential encompassing its activity in the cerebrospinal fluid (CSF) and its distinctive aptitude against lung infections, abdominal and dermal infections signifies that in upcoming era adjustments and refinements in the drug might give us a useful medicinal drug for clinical serviceability (Andriole, 1999).
Lomefloxacin has a bicyclic aromatic core with a Fluorine substitution at 8th carbon owing to its better oral absorption (Chu, Fernandes, 1989). Fluoro- substitution in aromatic core beneficial in escalating the drug’s penetration into the microbial cell and thus in return augment the activity of the drug. This substitution lead to the development of new generation of fluoroquinolone drugs (Kłosińska-Szmurło et al., 2014). A research study suggests that lomefloxacin when conjugated with copper iodide or copper thiocyanate become much more durable compounds with enhanced cytotoxicity properties. Lomefloxacin-copper complex when tested on three different tumor cell lines exhibited much better anti-tumor activity as compared to parent compound and cisplatin an anti-tumor drug (Komarnicka et al., 2016).

Fluoroquinolones are known to exert modulatory effects on immune response when given to treat bacterial diseases (Badari et al., 2015). In various incidents it was observed that beside inhibiting bacterial cell growth or multiplication antibiotics also have beneficial immunomodulatory effects in host against localized or systemic infections (Badari, El-Fatah, Kamel, 2014). Lomefloxacin similar to other fluoroquinolones boost in-vitro production of interleukin-2 but impedes the production of interleukin-1 and TNF-α, they also augment the production of CSF. By utilizing these pathways lomefloxacin act upon cellular and humoral immune processes by modifying cytokine levels and responses induced by them (Dalhoff, Shalit, 2003). In the current consideration, immunomodulatory effect on lomefloxacin in mice is to be evaluated. In this proposal we shall assess whether lomefloxacin potentiate or suppress immune system in mice.

MATERIAL AND METHODS

Experimental animals

Male albino mice 5-6 weeks old with weight between 25-30 grams were purchased from Department of Theriogenology, UVAS, Lahore. Mice were placed in clean environment with suitable temperature and humidity maintained. Standard pellet diet and water was given to all mice on regular basis during the research.

Chemicals

Lomefloxacin was purchased from Hubei Ocean Biotech, China via Scottman Pharmaceutical, Islamabad. Acetone, Dinitrochlorobenzene (DNCB), Phosphate buffer saline (PBS), Distil water for injection obtained from the Department of Pharmacology and Toxicology, UVAS, Lahore. Cyclophosphamide powder for injection was obtained from Clinix Pharmacy, Lahore.

Antigens

2% DNCB suspension was used in delayed type hypersensitivity assay as antigen. Sheep RBC’s obtained from sheep available at animal house of UVAS, Lahore, and used as antigen in heamagglutination assay. Pasteurella multocida strains were taken by University Diagnostic lab, UVAS, Lahore and were used in mice lethality test.

EXPERIMENTAL DESIGN

The objective of the study was to evaluate the effect of lomefloxacin on immune system. Response of cell mediated immunity to lomefloxacin was determined by three tests, which were delayed type hypersensitivity test, cyclophosphamide induced neutropenia and carbon clearance test, whereas, humoral immunity response was examined by two assays, one was heamagglutination assay and the other was mice lethality test.

Mice were used as test animal and these were divided into 5 groups with 5 mice in each group. These groups were named as Group 1 Group 2, Group 3, Group 4 and Group 5. Group 1 was considered as negative control group and was administered water via injection. Cyclophosphamide was administered to Group 2 and named as positive control group. Lomefloxacin was administered intraperitoneally to Group 3, Group 4, and Group 5 at dose of 12.5 mg/kg, 25 mg/kg and 50 mg/kg, respectively. All ethical guidelines as indicated in institutional protocols were followed.

Delayed type hypersensitivity assay

In this test, two sides of the mice were used for application of DNCB solution. On 2nd day of the trial, hairs from left side of the mice were removed by surgical scissors and sensitizing dose i.e. 0.1 mL DNCB solution was applied. On 8th day of the trial, 0.2 mL DNCB solution was applied to right side of the mice. Change in skin thickness was measured after 24, 48 and 72 hours using vernier caliper (Sajid et al., 2007).
Cyclophosphamide induced neutropenic assay

In this assay 4 groups of mice were used. Group 2, 3 and 4 received three different doses of lomefloxacin and Group 1 received water for injection. On 10th day of trial, blood was withdrawn from the mice and collected in heparinized vacutainer tubes. (Total leukocyte count) TLC and (Differential leukocyte count) DLC were performed on the blood samples. Cyclophosphamide at the dose of 200 mg/kg was injected to all mice subcutaneously. On 13th day of the trial, blood was again collected by puncturing the heart of the mice and TLC and DLC was performed (Thomas et al., 2007).

Carbon clearance test

Lomefloxacin were administered to the Group 2, 3 and 4, whereas control groups received 1% carboxymethyl cellulose (CMC) orally. On the 7th day of trial, all animals were injected with indian ink dispersion intravenously. 50 µL of blood was withdrawn in EDTA solution at time interval of 0 and 15 mins. In order to lyse erythrocytes, blood samples were added to 2 mL of 0.1% sodium carbonate. Optical density was checked at 660 nm in a spectrophotometer (Bharani et al., 2010).

Heamagglutination assay

Lomefloxacin was administered to treatment groups for 28 days. Mice were injected with 0.5×10⁹ sheep red blood cells (SRBCs) intraperitonealy on 14th day and on 21st day. On the 28th day blood samples were collected in eppendorff tubes by puncturing the heart of mice. 96 well round bottom plates were used to perform the antibodies titre. 50 µL of PBS was added in each well and 50 µL of serum was added to each well. The plates were left intact for 2 hours and results were noted (Fulzele et al., 2003).

Mice lethality test

Lomefloxacin was given intraperitoneally to Group 2, 3 and 4 for 21 days. On 7th and 17th day, mice were immunized by hemorrhagic septicemic vaccine. On 21st day, mice were given 0.2 mL of pasteurella multocida culture subcutaneously. Animals were observed for 72 hours and mortality ratio was evaluated (Sudha et al., 2010).

Evaluation of immunomodulatory effects of lomefloxacin in mice

Cyclophosphamide induced neutropenic assay

In this assay 4 groups of mice were used. Group 2, 3 and 4 received three different doses of lomefloxacin and Group 1 received water for injection. On 10th day of trial, blood was withdrawn from the mice and collected in heparinized vacutainer tubes. (Total leukocyte count) TLC and (Differential leukocyte count) DLC were performed on the blood samples. Cyclophosphamide at the dose of 200 mg/kg was injected to all mice subcutaneously. On 13th day of the trial, blood was again collected by puncturing the heart of the mice and TLC and DLC was performed (Thomas et al., 2007).

Carbon clearance test

Lomefloxacin were administered to the Group 2, 3 and 4, whereas control groups received 1% carboxymethyl cellulose (CMC) orally. On the 7th day of trial, all animals were injected with indian ink dispersion intravenously. 50 µL of blood was withdrawn in EDTA solution at time interval of 0 and 15 mins. In order to lyse erythrocytes, blood samples were added to 2 mL of 0.1% sodium carbonate. Optical density was checked at 660 nm in a spectrophotometer (Bharani et al., 2010).

Heamagglutination assay

Lomefloxacin was administered to treatment groups for 28 days. Mice were injected with 0.5×10⁹ sheep red blood cells (SRBCs) intraperitonealy on 14th day and on 21st day. On the 28th day blood samples were collected in eppendorff tubes by puncturing the heart of mice. 96 well round bottom plates were used to perform the antibodies titre. 50 µL of PBS was added in each well and 50 µL of serum was added to each well. The plates were left intact for 2 hours and results were noted (Fulzele et al., 2003).

Mice lethality test

Lomefloxacin was given intraperitoneally to Group 2, 3 and 4 for 21 days. On 7th and 17th day, mice were immunized by hemorrhagic septicemic vaccine. On 21st day, mice were given 0.2 mL of pasteurella multocida culture subcutaneously. Animals were observed for 72 hours and mortality ratio was evaluated (Sudha et al., 2010).

Statistical analysis

Collected data were analyzed by statistic package for social sciences (SPSS). ANOVA was applied. Difference was considered significant at P < 0.05.

RESULTS AND DISCUSSION

Delayed type hypersensitivity assay

The impact of lomefloxacin on cellular immune system was evaluated delayed type hypersensitivity assay in which DNCB was used as antigen to provoke immune response in mice (Sajid et al., 2007). DNCB when applied on epidermis gets absorbed and attains access to lymphatic system and it abet several cell-mediated immune responses including pustules, irritation, increase in skin thickness and inflammation (Gaspari, Katz, Martin, 2016). Results indicate highly significant (P<0.01**) suppression of skin thickness after 24 hours of challenging dose (Figure 1). After 48 hours, lomefloxacin (12.5 mg/kg) exhibited increase (P<0.001***) in skin thickness, whereas, lomefloxacin at doses 25 mg/kg and 50 mg/kg showed very highly significant (P<0.001***) suppression of skin thickness. After 72 hours lomefloxacin at 12.5 mg/kg exhibited very highly significant (P<0.001***) suppression of skin thickness, whereas, lomefloxacin at 25 mg/kg and 50 mg/kg exhibited high significantly (P<0.001**, P<0.05*) increase in skin thickness.

Cyclophosphamide induced neutropenic assay

Cyclophosphamide induced neutropenia assay was designed to assess the effects of lomefloxacin on mice with leukopenia. Cyclophosphamide besides being antitumor drug also possess immunosuppressant properties (Zuluaga et al., 2006). In current study, TLC and DLC before and after subcutaneous administration of cyclophosphamide were evaluated. TLC results depicted very highly significant (P<0.001***) decrease in leukocyte count in lomefloxacin 12.5 mg/kg group and significant (P<0.05*) decrease in leukocyte count in 25 mg/kg and 50 mg/kg group on 10th day of the trial. Very highly significant (P<0.001***) reduction in leukocyte count was observed in all the three lomefloxacin treated groups on 13th day of the trial [Figure 2(A)]. DLC was performed to assess effects of lomefloxacin on lymphocytes, monocytes and neutrophils. Highly
significant (P<0.01**) reduction in lymphocyte count was observed at dose 12.5 mg/kg and 50 mg/kg and at 25 mg/kg significant (P<0.05*) decrease in lymphocyte count was reported after cyclophosphamide injection [Figure 2(b)]. Cyclophosphamide suppress lymphocytes by inducing myeloid-derived suppressor cells (MDSC) (Gabrilovich, Nagaraj, 2009). MDSC are cells of immune system that are derived from myeloid origin but contrary to other cells of myeloid origin MDSC suppress immune responses instead of potentiating immune response (Diaz-Montero et al., 2009). Very highly significant (P<0.001***) reduction in monocyte count was noticed at dose of 12.5 mg/kg in contrast to dose 25 mg/kg and 50 mg/kg, which resulted in highly significant (P<0.001***, P<0.05*) increase in monocyte count [figure 2(C)]. Monocytes are usually short lived and undergo apoptotic cell death every 24 hours (Parihar, Eubank, Doseff, 2010). Increase in monocytes and neutrophils indicate that lomefloxacin may have potentiating effect on myeloid progenitor cells similar to moxifloxacin which suppress immune responses but induce monocytes and neutrophil production by acting on myeloid progenitor cells (Shalit et al., 2001). Highly significant (P<0.01**) augmentation in neutrophil number was observed after administration of cyclophosphamide in 12.5 mg/kg and 50 mg/kg treatment groups and significant (P<0.05*) augmentation was noticed in case of 25 mg/kg treatment group [Figure 2(D)]. These results indicate that increase in monocyte count and neutrophil count owe to the unique property of flouroquinolones. Flouroquinolones suppress the immune response but enhance the monocytes and neutrophil count by acting on myeloid progenitor cells.
FIGURE 2 (A) - Leukocytes count before and after cyclophosphamide administration.

FIGURE 2 (B) - Lymphocytes count before and after cyclophosphamide administration.
**Heamagglutination assay**

This assay was done to appraise the effect of lomefloxacin on reticulo endothelial system (RES) (Hajra, Mehta, Pamndey, 2012). RES consist of phagocytic cells primarily monocytes and macrophages which mostly assemble in spleen or lymphatic system (Govinda, Asdaq, 2011). When ink was administered intravenously in mice, macrophages engulfed the carbon particulates of Indian ink and percentage of removal of carbon particles from the blood is known as phagocytic index (George et al., 2014). Control group depicted immunosuppressant effects, whereas, lomefloxacin treated groups showed highly significant (P<0.01**) immunostimulatory effects (Figure 3). At dose 12.5 mg/kg and 25 mg/kg, phagocytic index was greater than 50 mg/kg indicating that injected carbon particles were immediately engulfed by macrophages in lomefloxacin treated groups compared to control group. Immunosuppressant effect in control group is due to slow clearance of CMC from blood stream, whereas, lomefloxacin, an antibiotic that also has immunosuppressant effects but a unique feature of stimulating myeloid progenitor cells resulted in enhanced production of macrophages which resulted in faster clearance of carbon particles after being injected with Indian ink (Singh, Yadav, 2014).
Humoral immune response is acquired by generation of antibodies against the specific antigen (Vos et al., 2000). Antibodies bind with the specific antigen and neutralize it or form meshwork that is engulfed by phagocytic cells (Dashputre, Naikwade, 2010). Binding of antibodies with sheep RBCs lead to the formation of agglutination in the 96 well round bottom plate which was reported as positive result, whereas, in cases when no antibodies were produced, sheep RBCS settled down leading to bead formation such cases were reported as negative result (Fulzele et al., 2003). Negative control group resulted paramount generation of antigen antibody complexes, whereas, positive control group exhibited least agglutination. Lomefloxacin treated groups resulted in very highly significant (P<0.001***) dose associated decrement of antibodies formations (Figure 4). These results are a clear indication that lomefloxacin has immunosuppressant effects.
Mice lethality test

One of the most widely used serological test is mice lethality test in which mice are challenged with Pasteurella multocida toxin after being vaccinated with HS-vaccine (Finco-Kent et al., 2001). PM-toxin induces a protein which enhance many cellular transduction pathways by stimulating G proteins leading to mutogenesis (Orth, Aktories, 2010). Mortality rate indicates the presence or absence of antibodies in mice serum against the toxin (Johnson et al., 2006). Mortality rate increased with increasing dose of lomefloxacin indicating immunosuppressant properties of drug. 20% mice died in negative control group, 80% died in positive control group, whereas, dose dependent mortality was observed in lomefloxacin treated groups that is 60%, 80% and 100% mice died at dose 12.5 mg/kg, 25 mg/kg and 50 mg/kg, respectively (Figure 5).

The results suggest that lomefloxacin possess immunomodulatory effects. Lomefloxacin supresses the humoral immune system in dose dependent manner while it exhibits suppressive effects on cell mediated immune system at specific doses. Lomefloxacin beside suppressive effects on immune system also has some modulatory effects on myeloid cells and myeloid derived suppressor cells which may need further research in order to develop new medicinal use of lomefloxacin beside its antibacterial effects. Lomefloxacin may be useful in medicinal conditions like autoimmune disease treatments, organ transplant surgeries or tumor because of its immunosuppressive potential.

**CONCLUSION**

This study clearly depicts that lomefloxacin possess potential to affect both innate and adaptive immune system. The immunomodulatory effects of this drug could be helpful in treatment of patients suffering from autoimmune disease and could also be useful in cancer treatment. Further research on cocrystalization of this drug with other salts and deep analyses of its effects on immune system in cancer patients and immunocompromised patients could lead to better understanding and better usage of the drug.

**ACKNOWLEDGMENT**

This research work was conducted in Department of Pharmacology and Toxicology, UVAS, Lahore and financial support for completion of this research project was also provided by Department of Pharmacology and Toxicology, UVAS, Lahore.

**CONFLICT OF INTEREST**

The authors have no conflict of interest.
REFERENCES


Received for publication on 13th September 2018
Accepted for publication on 14th November 2018